4,716 members and growing, are your details correct please LOGIN and update NOW
HCSA EIS EVENTs 2025 DATES LAUNCHED - Midlands/Birmingham- 1st May, North/Leeds - 5th June, South/Reading - 3rd July
Women's Network Event back for 3rd Year on 10th September 2025 in Birmingham
HCSA/HFMA Joint Procurement Event 22nd January 2025 last few places available
HCSA Annual Conference 19 & 20 November 2025 Telford International Centre ON SALE Early in 2025
HCSA Awards going live earlier in 2025 so start collecting those great award winning examples
Close Search

Smith & Nephew has become the latest company to record trading being hit in China as the country’s economy struggles.

The FTSE 100 manufacturer of medical products has cut its full-year target for revenue owing to issues in China, as it faces the twin threats of weak consumer demand and difficulties with the country’s new bulk-buying procurement strategy.

The group has reduced its guidance for revenue growth from between 5 per cent and 6 per cent to 4.5 per cent, prompting its share price to decline by 12.5 per cent, or 137p, to close at 961p.

Smith & Nephew said it had recorded “slower in-market demand” for its orthopaedic products such as hip and knee implants from Chinese consumers.

The market for medical goods has also been knocked by the country’s push to create more competitive tenders for pharmaceuticals and devices through its so-called volume-based procurement programme.

The drive has reduced prices paid by cities and provinces for products and has created a headwind for Smith & Nephew. The programme was meant to deliver higher sales volumes to compensate for lower prices, but Smith & Nephew warned the volume increases were “yet to come through” and it said the issues were expected to continue into 2025.

Source: The Times

Date: 6 November

Posted in News on Nov 06, 2024

Back to News